CompletedNot Applicable

Motor Evoked Potentials With Modified Facilitation Technique

Switzerland81 participantsStarted 2017-12-20

Plain-language summary

Investigating the change in Test- Retest- reliability in healthy individuals when applying a modified easy to use facilitation technique compared to standard facilitation technique and analyzing sensitivity and specificity in patients with multiple sclerosis regarding detection of pathologic results

Who can participate

Age range

18 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria for healthy individuals: * Ability to understand the purpose and risks of the study, provide signed and dated informed consent * Between 18 and 65 year of age * No neurologic or psychiatric comorbidity requiring continous treatment * No previous damage of central nervous System Inclusion Criteria for patients: * Ability to understand the purpose and risks of the study, provide signed and dated informed consent * Between 18 and 65 year of age * patients with inflammatory diseases of the central nervous system (CNS) or multiple sclerosis appointed for routine MEP diagnostic at the Department of Clinical Neurophysiology, University Hospital Basel Exclusion Criteria: * Contraindication for measuring of motoric evoked potentials (MEP): metal implants (pacemaker, stents); known epilepsy oder previous epileptic fit * Known disease of the peripheral nervous system (polyneuropathy)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in Test- Re-Test reliability when using modified facilitation technique (compared to standard facilitation technique) in healthy individuals

Timeframe: measuring time 2 (75 minutes) maximal 1 month later than measuring time 1 (75 minutes)

comparison of sensitivity and specificity of modified facilitation technique and standard facilitation technique in patients with multiple sclerosis

Timeframe: 1 measuring time (90 minutes)

Trial details

NCT IDNCT03646929

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-01-15

View on ClinicalTrials.gov More Multiple Sclerosis trials